350 related articles for article (PubMed ID: 12212772)
1. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772
[TBL] [Abstract][Full Text] [Related]
2. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
Fisher A; Pittel Z; Haring R; Bar-Ner N; Kliger-Spatz M; Natan N; Egozi I; Sonego H; Marcovitch I; Brandeis R
J Mol Neurosci; 2003; 20(3):349-56. PubMed ID: 14501019
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.
Fisher A
Jpn J Pharmacol; 2000 Oct; 84(2):101-12. PubMed ID: 11128032
[TBL] [Abstract][Full Text] [Related]
4. Impact of muscarinic agonists for successful therapy of Alzheimer's disease.
Fisher A; Brandeis R; Haring R; Bar-Ner N; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
J Neural Transm Suppl; 2002; (62):189-202. PubMed ID: 12456063
[TBL] [Abstract][Full Text] [Related]
5. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update.
Fisher A
Curr Alzheimer Res; 2007 Dec; 4(5):577-80. PubMed ID: 18220527
[TBL] [Abstract][Full Text] [Related]
6. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives.
Fisher A; Michaelson DM; Brandeis R; Haring R; Chapman S; Pittel Z
Ann N Y Acad Sci; 2000; 920():315-20. PubMed ID: 11193170
[TBL] [Abstract][Full Text] [Related]
7. AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s Disease.
Fisher A; Bezprozvanny I; Wu L; Ryskamp DA; Bar-Ner N; Natan N; Brandeis R; Elkon H; Nahum V; Gershonov E; LaFerla FM; Medeiros R
Neurodegener Dis; 2016; 16(1-2):95-110. PubMed ID: 26606130
[TBL] [Abstract][Full Text] [Related]
8. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update.
Fisher A; Heldman E; Gurwitz D; Haring R; Karton Y; Meshulam H; Pittel Z; Marciano D; Brandeis R; Sadot E; Barg Y; Pinkas-Kramarski R; Vogel Z; Ginzburg I; Treves TA; Verchovsky R; Klimowsky S; Korczyn AD
Ann N Y Acad Sci; 1996 Jan; 777():189-96. PubMed ID: 8624083
[TBL] [Abstract][Full Text] [Related]
9. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors.
Fisher A
Neurodegener Dis; 2008; 5(3-4):237-40. PubMed ID: 18322400
[TBL] [Abstract][Full Text] [Related]
10. Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists.
Beach TG; Walker DG; Potter PE; Sue LI; Fisher A
Brain Res; 2001 Jun; 905(1-2):220-3. PubMed ID: 11423097
[TBL] [Abstract][Full Text] [Related]
11. Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment.
Genis I; Fisher A; Michaelson DM
J Neurochem; 1999 Jan; 72(1):206-13. PubMed ID: 9886071
[TBL] [Abstract][Full Text] [Related]
12. M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice.
Fisher A; Brandeis R; Chapman S; Pittel Z; Michaelson DM
J Neurochem; 1998 May; 70(5):1991-7. PubMed ID: 9572284
[TBL] [Abstract][Full Text] [Related]
13. The utility of muscarinic agonists in the treatment of Alzheimer's disease.
Messer WS
J Mol Neurosci; 2002; 19(1-2):187-93. PubMed ID: 12212779
[TBL] [Abstract][Full Text] [Related]
14. M1 receptors play a central role in modulating AD-like pathology in transgenic mice.
Caccamo A; Oddo S; Billings LM; Green KN; Martinez-Coria H; Fisher A; LaFerla FM
Neuron; 2006 Mar; 49(5):671-82. PubMed ID: 16504943
[TBL] [Abstract][Full Text] [Related]
15. Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice.
Seo H; Ferree AW; Isacson O
Eur J Neurosci; 2002 Feb; 15(3):498-506. PubMed ID: 11876777
[TBL] [Abstract][Full Text] [Related]
16. Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: an unifying hypothesis.
Fisher A; Brandeis R; Haring R; Eshhar N; Heldman E; Karton Y; Eisenberg O; Meshulam H; Marciano D; Bar-Ner N; Pittel Z
J Physiol Paris; 1998; 92(5-6):337-40. PubMed ID: 9789833
[TBL] [Abstract][Full Text] [Related]
17. The effects of the acetylcholinesterase inhibitor ENA713 and the M1 agonist AF150(S) on apolipoprotein E deficient mice.
Chapman S; Fisher A; Weinstock M; Brandies R; Shohami E; Michaelson DM
J Physiol Paris; 1998; 92(3-4):299-303. PubMed ID: 9789827
[TBL] [Abstract][Full Text] [Related]
18. Facilitation of memory performance by a novel muscarinic agonist in young and old rats.
Ruske AC; White KG
Pharmacol Biochem Behav; 1999 Aug; 63(4):663-7. PubMed ID: 10462196
[TBL] [Abstract][Full Text] [Related]
19. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.
Fisher A
Neurotherapeutics; 2008 Jul; 5(3):433-42. PubMed ID: 18625455
[TBL] [Abstract][Full Text] [Related]
20. Progress in medicinal chemistry of novel selective muscarinic agonists.
Fisher A; Karton Y; Heldman E; Gurwitz D; Haring R; Meshulam H; Brandeis R; Pittel Z; Segall Y; Marciano D
Drug Des Discov; 1993; 9(3-4):221-35. PubMed ID: 8400004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
